tirzepatide higher dose trial Doses of Zepbound and Mounjaro Being Tested Lilly Decides to Advance Tirzepatide

Reducing Cardiac Toxicity Cyclodextrins can be used to reduce toxic cardiac effects of several drugs

Abstract Recent FDA approval of new GLP-1 agonists drugs focused on weight loss has been met with a surge in use of drugs such as Wegovy and Zebound

Insurance plans vary, but many now recognize semaglutide as essential for weight management

Patients have reported vision loss and damage to the optic nerve, including rare conditions like non-arteritic anterior ischemic optic neuropathy (NAION) and arteritic anterior ischemic optic neuropathy

PMC9794587

Beyond Glucagon-like Peptide-1: is G-Protein coupled receptor polypharmacology the path forward to treating metabolic diseases